EXTENDED REPORT

MICL controls inflammation in rheumatoid arthritis

Pierre Redelinguhyus, Lauren Whitehead, Andrea Augello, Rebecca A Drummond, Jean-Michel Levesque, Simon Vautier, Delyth M Reid, Bernhard Kerscher, Julie A Taylor, Peter A Nigrovic, John Wright, Graeme I Murray, Janet A Willment, Lynne J Hocking, Maria J G Fernandes, Cosimo De Bari, Iain B Mcinnes, Gordon D Brown

ABSTRACT

Background Myeloid inhibitory C-type lectin-like receptor (MICL, Clec12A) is a C-type lectin receptor (CLR) expressed predominantly by myeloid cells. Previous studies have suggested that MICL is involved in controlling inflammation.

Methods Clec12A−/− mice were generated commercially and primarily characterised using the collagen antibody-induced arthritis (CAIA) model. Mechanisms and progress of disease were characterised by clinical scoring, histology, flow cytometry, irradiation bone-marrow chimera generation, administration of blocking antibodies and in vivo imaging. Characterisation of MICL in patients with rheumatoid arthritis (RA) was determined by immunohistochemistry and single nucleotide polymorphism analysis. Anti-MICL antibodies were detected in patient serum by ELISA and dot-blot analysis.

Results MICL-deficient animals did not present with pan-immune dysfunction, but exhibited markedly exacerbated inflammation during CAIA, owing to the inappropriate activation of myeloid cells. Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA. In wild-type mice the administration of such antibodies recapitulated the Clec12A−/− phenotype.

Conclusions MICL plays an essential role in regulating inflammation during arthritis and is an autoantigen in a subset of patients with RA. These data suggest an entirely new mechanism underlying RA pathogenesis, whereby the threshold of myeloid cell activation can be modulated by autoantibodies that bind to cell membrane-expressed inhibitory receptors.

INTRODUCTION

The natural killer gene complex (NKC) encodes a multitude of activating and inhibitory C-type lectin receptors (CLRs), many of which play important roles in the maintenance of immune homeostasis. Loss or mutations in inhibitory CLRs, in particular, are often associated with unchecked inflammation and destructive autoimmunity. Notably, the NKC has been associated with rheumatoid arthritis (RA), but to date only one receptor within this cluster, dendritic cell immunoreceptor (DCIR), has been linked to this disease in humans. Myeloid inhibitory C-type lectin-like receptor (MICL) (also known as DCAL-2, CLEL-1 or KRL1) is an inhibitory receptor found in the ‘Dectin-1 cluster’ within the NKC, whose physiological function is unknown. MICL is highly expressed on myeloid cells, particularly neutrophils, monocytes and macrophages. It possesses a single extracellular C-type lectin-like domain, that recognises endogenous ligand(s), and a cytoplasmic tail containing an immunoreceptor tyrosine-based inhibitory motif that can transduce intracellular inhibitory signals. MICL-mediated intracellular signalling can modulate several cellular responses, and expression levels of this receptor are substantially altered during cellular activation. suggesting that it has an immune regulatory role. Recent evidence suggests that MICL can regulate inflammation in response to cell death.

There is also evidence implicating MICL in the pathogenesis of RA. We have previously described a potential link of polymorphisms in this receptor with RA pathogenesis. Moreover, expression of this receptor was shown to correlate with levels of rheumatoid factor (RF) in patients with RA. Here we have explored the physiological function of MICL and its role in RA.

METHODS

Mice

Clec12A−/− mice (Clec12A−/−) on a C57BL/6 background were produced by Taconic Artemis, USA (see online supplementary figure S1A). Clec12A−/− and wild-type (wt) mice were bred and maintained at the Medical Research Facility, University of Aberdeen. Mice were separately housed in groups and provided freely with food and water. All experimentation conformed to the terms and conditions of UK Home Office licences for research on animals (PPL 60/4007) and the University of Aberdeen ethical review committee.

Characterisation of MICL expression in 8–12-week-old wt and Clec12A−/− mice was performed by flow cytometry on cells isolated from the peripheral blood, bone marrow, peritoneal cavity, spleen and lungs, as previously described. Antibodies used in these experiments included biotin anti-MICL monoclonal antibody 3097 and isotype control, as well as biotin-Gr-1, FITC-7/4, PE-F480, biotin-F480, PerCpCy5.5-CD11b, PE-CCR3, biotin-NK1.1, PE-CD49.


Copyright Article author (or their employer) 2015. Produced by BMJ Publishing Group Ltd (& EULAR) under licence.
PerCpCy5.5-B220, PE-CD19, PerCpCy5.5-CD3, biotin-CD4, FITC-CD8, biotin-CD11c, PerCpCy5.5-Gr-1, APC-Ly6G, PE-CD11b, PE-Ly6G, PECy7-CD11b, Alexa Fluor 488 anti-STAT5, APC-streptavidin (all from BD Biosciences), and Alexa Fluor 700-F4/80 (BioLegend). Flow cytometry was undertaken using a BD LSRFortessa cell analyser and data analysed using FlowJo.

Models of inflammation and infection
Mice were injected intraperitoneally (IP) with 1.0 mL Brewer’s thioglycollate broth (BD Biosciences) or challenged intratracheally with either 100 ng lipopolysaccharide (LPS) or 1×10⁷ highly purified β₁,3-glucan particles. Cellular inflammation was analysed by flow cytometry 24 h later, unless otherwise indicated. To characterise resistance to systemic infection, mice were injected intravenously (IV) with Candida albicans SC5314, and fungal burdens and survival determined as described previously. The role of MICL in adaptive immunity was explored by adoptively transferring 3×10⁶ carboxyfluoresceinsuccinimidyl ester-labelled CD45.1+ CD4+ OT.II cells into gender-matched recipient mice, which were subsequently immunised with 50 μg ovalbumin (Hyglos GmbH) in complete Freund’s adjuvant (Difco). OT.II T cell responses were characterised at day 4 after immunisation by flow cytometry.

Collagen antibody-induced arthritis
Mice were injected IV with 4 mg of ArthritoMab monoclonal antibody cocktail (MD Biosciences), and then IP 3 days later with 100 μg LPS (MD Biosciences). In some experiments, 0.7 mg of anti-MICL or isotype control antibodies were administered IP every 24 h from day 4 to day 13. Daily clinical scoring was undertaken using a scale of 0 (no visible signs of redness or swelling) to 4 (extensive swelling with signs of deformity). To generate radiation chimeras, animals received 2×500 rad (IBL437C irradiator, Cis Bio International) and were then reconstituted with 2–4×10⁶ bone marrow cells from donor mice. For histology, joints were isolated, fixed, decalcified, sectioned and stained with H&E. In vivo imaging was performed using a Bruker in vivo MS FX Pro imager, after a single IV administration of OsteoSense 680EX (NEV10020EX, PerkinElmer, UK), 24 h before the start of the collagen antibody-induced arthritis (CAIA) protocol. Twenty-four hours before image acquisition, animals were also injected IV with ProSense 750EX (NEV10001EX, PerkinElmer, UK).

Human samples
Immunohistochemistry was performed on synovial tissue sections from patients with RA using CD163 (AbD Serotec), anti-human MICL (anti-hMICL) HB3 or an IgG1 isotype control.
(Sigma, Oakville, Ontario, Canada). Western blotting of synoviocyte cell suspensions with anti-MICL HB3 and horseradish peroxidase-conjugated sheep anti-mouse IgG was performed using standard methodology. Anti-hMICL was detected in serum samples of controls and patients with RA by ELISA, using immobilised highly purified recombinant Fc-hMICL (see online supplementary figure S2A) or Fc-Dectin-1. Bound antibodies were detected using horseradish peroxidase-conjugated goat anti-human IgG F(ab')2 fragment (Jackson ImmunoResearch). Specificity of this assay could be demonstrated by inhibition of serum antibody binding with the addition of soluble Fc-MICL (see online supplementary figure S2B). For dot blots, serum samples were used to probe recombinant histidine-tagged hMICL or histidine-tagged human C-type lectin superfamily member 8 (ClecSF8; Creative Biomart), immobilised on nitrocellulose membranes and then detected with peroxidase-conjugated goat anti-human IgG F(ab')2 fragment (Jackson ImmunoResearch) or mouse anti-His monoclonal antibody (Qiagen).

Serum samples from patients with RA (see online supplementary table S3) were obtained with consent from the Institute of Infection, Immunity and Inflammation Research Tissue Bank, Gartnavel General Hospital, Glasgow, UK and with ethical approval from the West of Scotland research ethics service. Serum samples were also obtained from consenting healthy donors with the approval of the College of Life Sciences and Medicine ethics review board, University of Aberdeen.

**Statistical analysis**

Two group analyses were performed using Student t tests, whereas one-way analysis of variance with Bonferroni’s multiple comparison test was used for multiple comparisons. Survival was assessed by the log-rank test. All statistical analyses were performed with GraphPad Prism software V.5.04.

**RESULTS**

**MICL deficiency does not result in pan-immune regulatory dysfunction**

To explore a possible immune regulatory role for MICL, we generated Clec12A−/− mice using conventional gene targeting, and confirmed the deletion of exons 1–4 of the gene encoding this receptor (Clec12A), corresponding to the cytoplasmic tail, transmembrane, stalk and part of the C-type lectin domain, by Southern blot and PCR analyses (see online supplementary figure S1 and data not shown). Flow cytometry of cells and tissues confirmed that MICL expression was abrogated (figure 1A and see online supplementary figure S3). The MICL−/− knockout mice were viable and had normal bone marrow (see online supplementary table S1) and peripheral blood leucocyte counts (see online supplementary table S2). Notably, unlike other inhibitory CLRs, including DCIR, Clec12A−/− mice did not exhibit any gross abnormalities during the first 12 months of life (data not shown), suggesting that loss of MICL does not result in the spontaneous development of autoimmunity.

To evaluate immune regulatory functionality, we first explored the effect of MICL deficiency in a model of sterile peritonitis induced by thioglycollate. After in vivo challenge, peritoneal expression of MICL on leucocyte subsets reached a peak at 4 h and then slowly decreased over time (figure 1B). Characterisation of the composition of the cellular infiltrates in the Clec12A−/− mice at several time points did not, however, reveal any defects in inflammation (figure 1C). Moreover, MICL deficiency had no effect on peritoneal inflammation induced by several other stimuli (see online supplementary figure S4). In addition, the knockout mice did not exhibit any abnormalities in pulmonary inflammation induced by various agonists (figure 1D) or resistance to systemic infection, using a fungal infection model (figure 1E). Although MICL has been shown to regulate dendritic cell function and influence the development of adaptive immunity, we did not detect any differences in the number, division or activation of antigen-specific CD4+ T cells in the draining lymph nodes of immunised Clec12A−/− mice (figure 1F). Consistent with previous reports using another knockout mouse line, we concluded that Clec12A−/− mice do not exhibit pan-immune regulatory dysfunction.

**MICL is required to control inflammation in murine models of collagen antibody-induced arthritis**

We next examined the effects of MICL deficiency during CAIA. This model was chosen as it induces an inflammatory polyarthritis reminiscent of the human disease and works efficiently on
the C57BL/6 background. In contrast to our results described above, we elicited substantial regulatory deficit during CAIA in Clec12A−/− mice (figure 2A). The peak of disease occurred around day 7 in wt mice and subsequently resolved around day 13. In the Clec12A−/− mice disease severity was enhanced, with a delayed zenith response (till day 11) and failed to resolve such that, by day 20, animals still exhibited considerable articular inflammation (figure 2A). Histological analysis showed mixed leucocytic inflammatory infiltrates and signs of periarticular bone erosion in the joints of the knockout mice (figure 2B). In vivo imaging revealed increased bone remodelling (see online supplementary figure S5) and inflammation (figure 2C) in the MICL-deficient animals. Together, these data suggest that MICL plays a fundamental role in controlling the pathology of CAIA.

To gain mechanistic insight, we characterised the peripheral blood of wild-type and MICL-deficient mice during CAIA. We observed a significant reduction in Gr-1hiCD11bhi neutrophils in the Clec12A−/− mice, consistent with the increased inflammation seen in these animals (figure 3A and online supplementary figure S6). In line with the loss of an inhibitory receptor, MICL-deficient cells expressed increased phosphorylated STAT-5 during CAIA (figure 3B), indicating enhanced myeloid cell activation, a phenotype similar to that seen in mice lacking the related receptor, DCIR.

To confirm that the phenotype of the Clec12A−/− mice stemmed from the myeloid compartment, we generated irradiation-derived bone marrow chimeric mice (figure 3C and see online supplementary figure S7). Reconstitution of wild-type or Clec12A−/− mice with MICL-knockout bone marrow exacerbated CAIA and prevented resolution of the disease, as before (figure 3C, right panels). In contrast, there was a reversion to normal progression and resolution of CAIA in Clec12A−/− animals that had received wild-type bone marrow (figure 3C, left panels). These data demonstrate that the phenotype of Clec12A−/− mice during CAIA stems from inappropriate regulation of myeloid cells.

**MICL is an autoantigen in a subset of patients with RA**

To translate the relevance of these observations to human disease, we first examined the expression of hMICL in the synovium of patients with RA and controls, using monoclonal antibodies which are specific for human MICL. Immunohistochemical analysis disclosed the presence of hMICL in the synovial lining layer and in scattered subsynovial cells of patients with RA, but that there was little or no expression in non-inflamed synovium (figure 4A). Western blotting of RA synovial cell lysates further confirmed expression of the various glycoforms of MICL (see online supplementary figure S8). Staining of serial sections with CD163 suggested that MICL was expressed on cells of the macrophage/monocytic lineage in inflamed synovial tissue (figure 4B).

The gene cluster in which MICL is located has been linked with RA, and we recently reported that polymorphisms of hMICL could potentially be associated with this disease. We reassessed the contribution of this gene within the much larger cohort of the Wellcome Trust Case Control Consortium.

**Figure 3** Exacerbated collagen antibody-induced arthritis (CAIA) in Clec12A−/− mice stems from inappropriate myeloid cell activation. (A) Percentage of Gr-1hiCD11bhi neutrophils and (B) expression of phosphorylated Stat-5 (pY694) at day 10 after immunisation. Data are shown as mean±SEM of pooled data from four independent experiments (n=8–24). *p<0.05. MICL, myeloid inhibitory C-type lectin-like receptor.

(A) Immunohistochemical analysis of expression of hMICL (brown) in haematoxylin-stained synovial tissue sections from three patients with RA (top panels) and non-inflamed synovium from a patient with osteoarthritis (bottom panels). (B) Immunohistochemical analysis of serial sections of RA synovium probed for CD163 or antiMCL, as indicated. Sections were counterstained with haematoxylin. Scale bar, 50 μm.
However, there was no genome-wide significant association of any polymorphism in and around Clec12A with RA (figure 5).

Expression of hMICL has also been correlated with raised levels of RF, so we next explored the possibility that hMICL was a target of autoantibodies in patients with RA. Notably, we could demonstrate serum reactivity to hMICL in more than 60% of patients with RA tested by ELISA, and no reactivity in healthy controls (figure 6A). These serum samples were selected at random from a small cohort of RF-positive and anti-citrullinated protein antibody (ACPAs)-positive patients with RA (see online supplementary table S3). To confirm this observation by an alternative method, we also directly demonstrated this serum reactivity by dot-blot analysis under native conditions (figure 6B). Serum reactivity was abolished under non-native conditions (see online supplementary figure S9). We did not detect any correlation between serum antibody levels and C-reactive protein levels or 28-joint count Disease Activity Scores in these patients (see online supplementary figure S10). Thus, these data demonstrate that a subset of patients with RA develop autoantibodies to MICL.

To determine whether anti-MICL antibodies could functionally influence the progression of arthritis, we turned to our animal models. For these experiments, we administered anti-mMICL monoclonal antibodies IP every 24 h from day 4 to day 13, after induction of CAIA in wild-type mice. We have previously described these antibodies and shown that they are specific for murine MICL. Remarkably, administration of these monoclonal antibodies increased the severity of the disease and prolonged its duration, reminiscent of the phenotype seen in the Clec12A−/− mice (figure 6C). Thus these results demonstrate that antibodies to MICL can exacerbate arthritic inflammation.

**DISCUSSION**

Myeloid cells are considered central to RA pathogenesis. In this study we show that MICL can directly regulate the activation of myeloid lineage cells in inflammatory articular responses. The increased pSTAT-5 levels seen in the Clec12A knockout mice, and the previously demonstrated ability of MICL to control cellular responses, indicate that the inhibitory signalling induced by this receptor is essential to control inflammation during CAIA. These functions of MICL are probably triggered following the recognition of cell death, which occurs in the synovium during active inflammation.

Although MICL is not genetically associated with RA in humans (Okada et al and this study), we have discovered that this receptor is the target of autoantibodies in a subset of these patients. Although our cohort size was small, the production of autoantibodies, particularly ACPA, is a key feature in RA, and they serve as important diagnostic and prognostic indicators. Recently, direct functional activities mediated by ACPA—for example, via FcR dependent pathways, and osteoclast...
maturation via citrullinated-vimentin recognition have attracted increasing attention.\textsuperscript{24} Importantly, we now demonstrate that anti-MICL antibodies can exacerbate disease, at least in murine models, suggesting a new means whereby resolution can fail and myeloid-dependent inflammation can prevail.

There is increasing realisation that failed resolution is pivotal in driving the evolution of RA from undifferentiated inflammatory arthritis. Given the central role of myeloid lineage cells in synovitis most attention has focused on activation pathways, including TLR, FcR, NLR, PAR2 and T cell-driven lectin-dependent interactions.\textsuperscript{22} That a deficient autoregulatory pathway may also contribute has thus far not been identified. We thus offer an entirely new mechanism underlying disease perpetuation, or failed resolution, in which the ‘threshold’ for myeloid cell activation is modulated by autoantibody to regulatory cell-surface receptors, directly influencing the severity and persistence of inflammatory synovitis. Although further work is required to confirm that these autoantibodies have functional effects, our observations have implications for the diagnosis, stratification and treatment of this disease in patients.

Acknowledgements We thank G Milne, D MacCallum, S Hardison, G Wilson, C Wallace, S Hadebe and A Richmond for assistance; H El-Gabalawy for tissues and the animal facility staff for the care of our animals. Flow cytometry was undertaken in the Iain Fraser Cytometry Centre, University of Aberdeen.

Contributors All authors contributed to this manuscript. Study concept and design: PR, CDB, IBM, GDB; acquisition of data: PR, LW, AA, RAD, J-ML, SV, DMR, BK, JAT, PAN, JW, JAW, LIH, MGIF; analysis and interpretation of data: PR, GIM, CDB, IBM, GDB.

Funding GDB was funded by the Wellcome Trust and MRC (UK). AA and CDB are supported by the Arthritis Research UK Tissue Engineering Centre (grant 19429). This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk, and was funded by the Wellcome Trust (076113). MGIF was funded by The Arthritis Society and the Canadian Arthritis Network and J-ML by a scholarship from the Canadian Arthritis Network.

Competing interests None declared.

Ethics approval West of Scotland research ethics service and the College of Life Sciences and Medicine ethics review board, University of Aberdeen.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
MICL controls inflammation in rheumatoid arthritis

Pierre Redelinghuys, Lauren Whitehead, Andrea Augello, Rebecca A Drummond, Jean-Michel Levesque, Simon Vautier, Delyth M Reid, Bernhard Kerscher, Julie A Taylor, Peter A Nigrovic, John Wright, Graeme I Murray, Janet A Willment, Lynne J Hocking, Maria J G Fernandes, Cosimo De Bari, Iain B Mcinnes and Gordon D Brown

Ann Rheum Dis published online August 14, 2015

Updated information and services can be found at:
http://ard.bmj.com/content/early/2015/08/14/annrheumdis-2014-2066 44

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2015/08/14/annrheumdis-2014-2066 44.DC1

References
This article cites 24 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/early/2015/08/14/annrheumdis-2014-2066 44#BIBL

Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (595)
Immunology (including allergy) (5144)
Inflammation (1251)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Connective tissue disease (4253)
Rheumatoid arthritis (3258)
Genetics (968)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/